Cataract after busulphan treatment

Abstract

Busulphan, first introduced into clinical practice by Galton in 1953, is the drug of choice in the treatment of chronic myeloid leukaemia. Cataract as a toxic effect of prolonged busulphan therapy has been reported only rarely (Podos and Canellos, 1969). This report describes the case of a young adult with chronic myeloid leukaemia who developed mature cataract in both eyes during busulphan therapy. © 1972, British Medical Journal Publishing Group. All rights reserved.